In conclusion, from the U.S. health care sector perspective, first-line N+I or N+I+chemotherapy was not cost-effective for patients with metastatic NSCLC regardless of tumor PD-L1 expressions levels at a willingness-to-pay threshold of $150,000 per QALY. Here, CD274 is linked to non-small cell lung carcinoma.